Previsão
O preço-alvo médio dos analistas é € 3,19 (+65,28%). A mediana é € 3,19 (+65,28%).
| Comprar |
3 |
| Manter |
1 |
| Vender |
1 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
Nautilus Biotechnology beats Q1 2026 EPS expectations and reports cost cuts
Nautilus Biotechnology reported Q1 2026 EPS of -0.12 versus a forecast of -0.17, beating expectations by 29.41%. The stock rose 11.63% in premarket trading. Operating expenses fell 14% year over year to $16.1 million, cash on hand is $143.4 million and is expected to fund the company through 2027. The company plans strategic hires and commercialization efforts with product launches toward the end of 2026, expects revenue of about $0.5 million for 2026, and cites risks of delays in revenue recognition. » Mais em de.investing.com
Nautilus Biotechnology unveils Voyager platform and secures liquidity through 2027
Nautilus Biotechnology presented the Voyager proteomics platform at an investor conference, with an early-access beta planned for H2 2026, along with partnerships and a focus on tau and oncology proteoform assays. The company reports a liquid cash position of $156 million, which is expected to fund operations through 2027. Forecasts project a proteomics market with a 13% CAGR through 2030 and an expected customer spend rate on consumables of around $500,000 per year. » Mais em de.investing.com
Nautilus Biotechnology unveils proteomics platform and plans market launch at end of 2026
At an investor conference, Nautilus Biotechnology presented its iterative mapping technology for complete proteome analysis and positions itself as a disruptive force in drug development. The platform is slated to launch at the end of 2026 at about $1 million per instrument; consumables are expected to cost a few thousand dollars per sample. The company cites an addressable market of $57 billion by 2030, holds $180 million in cash (sufficient through the end of 2027), and anticipates further funding rounds to scale. A collaboration with the Allen Institute is intended to validate applications for neurodegenerative diseases such as Alzheimer’s. » Mais em de.investing.com
Nautilus Biotechnology presents plans for comprehensive proteomics platform and market launch
At the Morgan Stanley Healthcare Conference, Nautilus Biotechnology presented its iMap-based platform for whole-proteome analysis and plans to launch the full solution by the end of next year, with an early-access program six months earlier. The technology shows high reproducibility and will initially be used in discovery proteomics and studies of tau proteins and Alzheimer’s. The company has about $180 million in liquidity, is considering flexible pricing models, and estimates the cost of a complete solution at roughly $1 million with consumables costing a few thousand dollars per sample. Nautilus cites market adoption and competition from niche solutions as challenges, is advancing manufacturing and software completion, and plans a phased rollout and collaborations with research institutions and pharma. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresEm 2022, Nautilus Biotechnology A já distribuiu € 0,0258 em dividendos. A última distribuição ocorreu em fevereiro de 2022.
Dados financeiros
No último trimestre, Nautilus Biotechnology A registou receitas de € 206,59 mil e um ganho líquido de -€ 13,8 mi
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 206,59 mil | - |
| Ganho bruto | 185,4 mil | - |
| Ganho líquido | -13,8 mi | 19,34% |
| EBITDA | -12,65 mi | 7,23% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 290,78 mi |
Número de ações | 127,37 mi |
Máximo/mínimo de 52 semanas | € 3,93 - € 0,77 |
| Dividendos | Não |
Beta | 0,87 |
PER (PE Ratio) | -5,45 |
PEG (PEG Ratio) | -0,67 |
P/VC (PB Ratio) | 2,73 |
P/V (PS Ratio) | 752,52 |
Perfil da empresa
A Nautilus Biotechnology, Inc., uma empresa de ciências da vida em fase de desenvolvimento, dedica-se à criação de uma plataforma tecnológica para quantificar e desvendar a complexidade do proteoma. Desenvolve a Nautilus Platform, uma plataforma de proteómica que inclui uma solução completa, composta por instrumentos, consumíveis e software de análise. A empresa foi fundada em 2016 e tem sede em Seattle, Washington.
| Nome | Nautilus Biotechnology A |
| CEO | Sujal Patel |
| Sede | Seattle,
wa EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: equipamentos e produtos |
| Entrada em bolsa | 24/02/2016 |
| Colaboradores | 128 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | NAUT |